| Metric | FY2025 | FY2024 |
|---|---|---|
| Total revenues | $3.9M | $0 |
| Research and development | $53.1M-4.3% | $55.5M |
| Acquisition of in-process research and development | $530.0M | $0 |
| General and administrative | $65.1M+36.9% | $47.5M |
| Total operating expenses | $648.1M+529.3% | $103.0M |
| Loss from operations | -$644.1M-527.2% | -$102.7M |
| Interest income | $1.5M+90.0% | $778K |
| Interest expense | -$1.2M+62.8% | -$3.1M |
| Change in fair value of assets and liabilities, net | -$24.4M+50.0% | -$48.9M |
| Gain on other investments | $3.8M+201.1% | $1.3M |
| Gain on consolidation of Beckley Psytech | $6.9M | $0 |
| Change in fair value of digital assets, net | -$1.2M | $0 |
| Foreign exchange loss, net | $1.9M+251.1% | -$1.3M |
| Other income (expense), net | -$15.8M+65.5% | -$45.7M |
| Net loss before income taxes | -$659.8M-344.6% | -$148.4M |
| Benefit from (provision for) income taxes | -$298K-183.7% | $356K |
| Losses from investments in equity method investees, net of tax | $0+100.0% | -$2.0M |
| Net loss | -$660.1M-340.0% | -$150.0M |
| Net loss attributable to noncontrolling interests | -$100K+87.2% | -$780K |
| Net loss attributable to ATAI Life Sciences N.V. stockholders | -$660.0M-342.2% | -$149.3M |
| Net loss per share attributable to AtaiBeckley Inc. shareholders - basic | -$2910.00-212.9% | -$930.00 |
| Net loss per share attributable to AtaiBeckley Inc. shareholders - diluted | -$2910.00-212.9% | -$930.00 |
| Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - basic | $226.53B+41.4% | $160.16B |
| Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - diluted | $226.53B+41.4% | $160.16B |
| License Revenue | ||
| Research and Development Services Revenue | ||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.